Non-ionic surfactant vesicles mediated transcutaneous immunization against hepatitis B

Maheshwari, Chetan; Pandey, Ravi Shankar; Chaurasiya, Akash; Kumar, Adarsh; Selvam, Deepak; Prasad, G. V. R.; Dixit, Vinod Kumar

doi:10.1016/j.intimp.2011.05.007

Cited by 37 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTB showed the ability to not only enhance the immune response against HBsAg but also extend the duration of protection through the transcutaneous immunization route [ 74 ]. Combined with results of other studies using a similar strategy [ 75 , 76 , 77 , 78 ], there is now a compelling reason to explore the development of transcutaneous vaccines including CTB as an adjuvant.…”

Section: Ctb As a Vaccine Adjuvantmentioning

confidence: 99%

Cholera Toxin B: One Subunit with Many Pharmaceutical Applications

Baldauf

Royal

Hamorsky

et al. 2015

Toxins

157

121

View full text Add to dashboard Cite

Cholera, a waterborne acute diarrheal disease caused by Vibrio cholerae, remains prevalent in underdeveloped countries and is a serious health threat to those living in unsanitary conditions. The major virulence factor is cholera toxin (CT), which consists of two subunits: the A subunit (CTA) and the B subunit (CTB). CTB is a 55 kD homopentameric, non-toxic protein binding to the GM1 ganglioside on mammalian cells with high affinity. Currently, recombinantly produced CTB is used as a component of an internationally licensed oral cholera vaccine, as the protein induces potent humoral immunity that can neutralize CT in the gut. Additionally, recent studies have revealed that CTB administration leads to the induction of anti-inflammatory mechanisms in vivo. This review will cover the potential of CTB as an immunomodulatory and anti-inflammatory agent. We will also summarize various recombinant expression systems available for recombinant CTB bioproduction.

show abstract

Section: Ctb As a Vaccine Adjuvantmentioning

confidence: 99%

Cholera Toxin B: One Subunit with Many Pharmaceutical Applications

Baldauf

Royal

Hamorsky

et al. 2015

Toxins

157

121

View full text Add to dashboard Cite

show abstract

“…Thirdly, the non-ionic surfactants play a crucial role in improving penetration by acting as penetration enhancers. Wherein vesicle bilayers enter the SC with subsequent modification of the intercellular lipids, which increases overall membrane fluidity (50,55,58,84,104,105,(107)(108)(109)(110)(111)(112). Lastly, niosomes cause an alteration in the SC properties through a reduction in the trans-epidermal water loss, thus leading to an increase in SC hydration with the loosening of its closely packed cellular structure (55,104).…”

Section: Topical and Transdermal Deliverymentioning

confidence: 99%

Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications

Chen

Hanning

Falconer

et al. 2019

European Journal of Pharmaceutics and Biopharmaceutics

331

176

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Mechanisms for transdermal enhancement of hydrophobic drugs include (i) disruption of lipid bilayer of the stratum corneum (SC)-structural modification of stratum corneum, i.e., the densely packed lipid bilayer, helps to fill up the extracellular spaces by a disruption to enhance the permeation rate; (ii) enhancement of transdermal permeation through nano-sizing; (iii) changing drug partition into skin layers; (iv) hydrating skin and the dilation of the SC intercellular channels-niosomes cause an alteration in the barrier property of stratum corneum, which enhances sc hydration by reducing trans-epidermal water loss, leading to loosening the tightly packed structure and lyses of the membrane by lysozyme and releasing the entrapped drug into the system [20][21][22][23][24][25][26]; and (v) changing the permeation pathway of lipophilic permeants to follicular delivery [27]. The non-ionic surfactants play a crucial role as a penetration enhancer that enters into the intercellular lipids through endocytosis [28,29].…”

Section: Possible Mechanisms Of Action Of Niosomes and Proniosomes Fomentioning

confidence: 99%

Recent advances of non-ionic surfactant-based nano-vesicles (niosomes and proniosomes): a brief review of these in enhancing transdermal delivery of drug

2020

Futur J Pharm Sci

View full text Add to dashboard Cite

Background Hepatic first-pass metabolism and poor therapeutic efficiency at targeted region are the endemic problems of new drug molecules. Thus, comprehensive research has been carried out on the novel vesicular drug delivery systems in nanotechnology from the last few years. These nano-carrier systems have developed to overcome the limitations that are associated with hepatic first-pass metabolism in conventional oral dosage forms and the barrier properties of the lipid bilayer in stratum corneum via transdermal drug delivery for improving the bioavailability of various drugs. Main body In recent years, several targeted vesicular drug delivery carriers are developing like liposomes, niosomes, proniosomes, transferosomes, ethosomes, and electrosomes. Among them, niosomes and proniosomes are to be better carriers to increase therapeutic efficiency and bioavailability by reducing the side effects and acting as a promising approach for transdermal drug delivery. Both are non-ionic surfactant-based vesicles and are amphiphilic. This article concisely reviews the possible mechanisms within niosomes and pronisomes to enhance transdermal drug delivery, types, composition, preparation techniques, characterizations, and its applications. Conclusion As per the researches done in the formulation of various nano-carrier systems through transdermal approach for the enhancement of bioavailability, it can be stated that the hepatic first pass metabolism can be reduced as well as therapeutic efficiency can be increased by many folds compared to their oral marketed formulations.

show abstract

Non-ionic surfactant vesicles mediated transcutaneous immunization against hepatitis B

Cited by 37 publications

References 27 publications

Cholera Toxin B: One Subunit with Many Pharmaceutical Applications

Cholera Toxin B: One Subunit with Many Pharmaceutical Applications

Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications

Recent advances of non-ionic surfactant-based nano-vesicles (niosomes and proniosomes): a brief review of these in enhancing transdermal delivery of drug

Contact Info

Product

Resources

About